Theravance Biopharma TBPH Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's retained earnings?
- Theravance Biopharma (TBPH) reported retained earnings of -$864.56M in Q1 2026.
- How has Theravance Biopharma's retained earnings changed year-over-year?
- Theravance Biopharma's retained earnings increased by 11.7% year-over-year, from -$979.1M to -$864.56M.
- What is the long-term trend for Theravance Biopharma's retained earnings?
- Over 5 years (2020 to 2025), Theravance Biopharma's retained earnings has grown at a -10.9% compound annual growth rate (CAGR), from -$1.53B to -$859.63M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.